Beximco Pharmaceuticals Limited

Trend Analysis

Statement of Financial Position

Current Assets Non-Current Assets

160 160
140 140
140 140
126
119
120 120
100 100
100 100

80 80

60 60

40 40

20 20

0 0 2018
2017 2017 2018 2019 2019
Column2
Column1

Shareholders'
Total assets Equity
120
160 118
140
140
115 124
120
100
100
110 108
80
105
60
100
40
100
20
95
0
2017 2018 2019
90
2017 2018 2019
Series 3

Non-Current
Current Liabilities Liabilities
and Provisions
400
200
178 349
180 350
160 300
140 238
250
120 112
200
100
100
150
80
100
60 100
40 50
20
0
2017 2018 2019
0
2017 2018 2019
Column2
Series 3
 Total Equity and Liabilities
160
140
140
124
120
100
100

80

60

40

20

0
2017 2018 2019

Column2
 Beximco Pharmaceuticals Limited

Trend Analysis

Statement of Profit or Loss and other Comprehensive Income

Cost
NetofSales
GoodsRevenue
Sold
160
160
140 137 136
140
120 120 111
112
100
100 100
100
80
80 60

60 40
20
40
0
2017 2018 2019
20

0
2017 2018 Series 3 2019

Series 3

Gross Profit
160
Operating Expenses
140 136
160
120 113
139
100 140
100
120 111
80
100
60 100

40 80

20 60

0
2017 2018 2019 40

Series 3 20

0 Series 3
2017 2018 2019
 Profit from Operations
160
Profit before Contribution to WPPF and Welfare Funds 139
140

120 115
160
100
140 100 135

120 116
80
100
100
60
80
40
60
40 20

20 0
2017 2018 2019
0
2017 2018 2019
Series 3

Series 3 Income
ProfitTax Expenses
before Tax
140
160 133
121
140
120 135

120100
100
116
100
100
80
80
60
60
40
40
20
20
0
0
2017 2018 2019
2017 2018 2019
Series 3
Series 3

Other Comprehensive Income-Unrealized Gain/(Loss) Profit After Tax for the Year
160

140 136
120
100 120 115
100
100
100
80 72

60 80

40 60
19
20 40
2
0
2017 2018 2019 20

0
2017 2018 2019

Series 2 Series 3 Series 3

 Total Comprehensive Income for the Year
Earnings Per Share
160
160
140 136
140 136
120 115
100 115
120 100
100
100 80
60
80
40
60
20
5
40
0
2017 2018 2019
20

0 Series 2 Series 3
2017 2018 2019
Beximco Pharmaceuticals Limited
Series 3
Trend Analysis

Statement of Retained Earnings

Closing Balance
160

140 137

120 116
100
100

80

60

40

20

0
2017 2018 2019

Series 3
 Net Asset Value (NAV) Per Share
120 118

115

110 108

105

100
100

95

90
2017 2018 2019

Series 3

Square Pharmaceuticals Limited

Trend Analysis

Statement of Financial Position

Current Assets Assets

Non-Current
200
120
111
180 172
100
100
160

140
80
122
120
100
60
100

80
40

60
20
40
3.5
200
2017 2018 2019
0 Series 3
2017 2018 Series 3 2019
 Total Assets
160
Shareholders' Equity 142
140

120 160 117

148
100140
100
120 113
80 100
100
60 80

40 60

20 40
20
0
2017 0 2018 2019
2017 2018 2019
Series 3
Series 3

Current Liabilities and

Non-Current Provisions
Liabilities
180
140
158 123
160
120
140 107
100
100
120
100
100
80
84
80
60
60
40
40

20
0
2017
0 2018 2019
2017 2018 2019
Series 3
Series 3
 Total Equity and Liabilities
160
142
140

120 117

100
100

80

60

40

20

0
2017 2018 2019

Series 3

Square Pharmaceuticals Limited

Trend Analysis

Statement of Profit or Loss and Other Comprehensive Income

Net Sales Revenue

160
Cost of Goods Sold
140 134

120 140 133

100 104
100 120 105
100
100
80
80
60
60
40
40
20
20
0
2017 2018 2019
0
2017 2018 2019
Series 3
Series 3
 Operating Expenses
Gross Profit
160
140 132
140 135
120 113
120100100
100 102
10080
60
80
40
60
20
40 0
2017 2018 2019
20

0
2017 2018 2019
Series 3
Series 3

Profit before Contribution

Profit from
to WPPF
Operations
and Welfare Funds

160
160
137
140 135
140
120
120
100
100100 10495
100
80
6080
4060
2040
0
20
2017 2018 2019
0
2017 2018 2019

SeriesColumn1
3
 Profit
Income Taxbefore Tax
Expenses
160

140 140 132 135

120
120
100 101
104
100 100
100
80
80
60
60
40
40
20
20
0
2017 2018 2019
0
2017 2018 2019

SeriesSeries
3 3

Other Comprehensive
Profit Income
After Tax for the Year
Unrealized Gain/(Loss)
160
140
140 136
120 117
120
100
100100 105
100
80
80
60
60
40
40
20
9
20
0
2017
0 2018 2019
2017 2018 2019
Series 3
Series 3

Total Comprehensive Income for the Year

140 130

120
100 97
100

80

60

40

20

0
2017 2018 2019

Series 3
 Earnings Per Share
160

140 136

120 115
100
100

80

60

40

20

0
2017 2018 2019

Series 3

Square Pharmaceuticals Limited

Trend Analysis

Statement of Retained Earnings

Closing Balance
180

160 153

140

120 117
100
100

80

60

40

20

0
2017 2018 2019

Series 3
 Net Asset Value (NAV) Per Share
160
138
140

120 113
100
100

80

60

40

20

0
2017 2018 2019

Series 3